Skip to content
Inciteful Med

Treatment Strategies: Medications vs. Surgery

Last updated:

For most prolactinoma patients, dopamine agonist medications like cabergoline are the first-line treatment and successfully shrink tumors. Transsphenoidal surgery is an excellent alternative if medications fail, cause severe side effects, or for certain large or fluid-filled tumors.

Key Takeaways

  • • Dopamine agonists like cabergoline are the first-line treatment and successfully shrink prolactinomas in about 90% of patients.
  • • Transsphenoidal surgery is an effective alternative for medication-resistant tumors, cystic tumors, or patients with severe medication side effects.
  • • Medications can cause side effects ranging from nausea and dizziness to less common impulse control disorders.
  • • Women planning a pregnancy must discuss treatment adjustments with their endocrinologist to manage tumor growth risks.
  • • Immediate surgery is required for rare emergencies such as pituitary apoplexy or rapid, severe vision loss.

Deciding on a treatment path for a prolactinoma involves weighing the effectiveness of medication against the possibility of a surgical cure. For the vast majority of patients, medication is the starting point, but surgery remains a vital and highly effective alternative in specific situations [1][2].

First-Line Treatment: Dopamine Agonists

The standard of care for a prolactinoma is a class of drugs called dopamine agonists (DAs). These medications work by mimicking dopamine, the brain’s natural “off switch” for prolactin production. They are highly effective, normalizing hormone levels and shrinking tumors in approximately 90% of patients [3][4].

  • Cabergoline vs. Bromocriptine: Cabergoline is typically the preferred first-line choice because it is more effective at normalizing prolactin and is generally better tolerated by patients [5]. Bromocriptine is an older alternative that is sometimes used, especially in certain pregnancy-related scenarios [5][6].
  • What to Expect: These drugs are designed to both lower your prolactin levels and physically shrink the tumor over time [7].

Managing Pregnancy

Because this treatment rapidly restores fertility, many women will become pregnant while on these drugs.

  • Plan Ahead: Always discuss a pregnancy plan with your endocrinologist before conceiving.
  • Protocol: Typically, dopamine agonists are stopped immediately upon a positive pregnancy test for microadenomas, while macroadenomas require specialized management (and sometimes continued medication) to prevent tumor growth during the pregnancy [8][9].

Common and Rare Side Effects

While effective, DAs can cause side effects that range from mild to significant.

  • Physical Symptoms: Nausea, dizziness, and low blood pressure (especially when standing up) are common when first starting the medication [10][11]. Practical Tip: Taking your medication at bedtime or with a meal can help reduce these side effects.
  • Impulse Control Disorders (ICDs): A less common but important side effect involves new, compulsive behaviors such as pathological gambling, excessive shopping, or hypersexuality [12][13]. It is important for you and your family to monitor for these behavioral changes [12].
  • CSF Leak: In rare cases of very large, invasive tumors, the medication may shrink the tumor so quickly that it “unplugs” a pre-existing hole in the bone at the base of the skull, leading to a cerebrospinal fluid (CSF) leak (fluid dripping from the nose) [14][15]. This is a rare event. If you experience a sudden rush of clear fluid from your nose, treat this as a medical emergency and contact your care team immediately.

When Surgery is the Better Option

Transsphenoidal Surgery (TSS)—a procedure where a surgeon reaches the pituitary through the nose—is no longer just a “last resort.” It may be recommended as a primary or secondary option in several cases:

  • Medication Resistance: If high doses of medication fail to lower prolactin or shrink the tumor (which happens in about 10–20% of cases) [16][17].
  • Intolerance: If the side effects of the medication are too severe for you to continue [18].
  • Pregnancy Planning: Women with large tumors may choose surgery before getting pregnant to prevent the tumor from growing while they are off medication during pregnancy [8].
  • Cystic Tumors: Tumors that are primarily fluid-filled (cysts) rather than solid tissue often do not shrink well with medication and may respond better to surgery [19].
  • Emergencies: Immediate surgery is necessary for pituitary apoplexy (sudden bleeding into the tumor) or if the tumor is causing rapid, severe vision loss [20][21].

Decision Framework

Consideration Medication (Dopamine Agonists) Surgery (Transsphenoidal)
Success Rate ~90% for hormone control/shrinkage [3]. ~90% for micro; ~70% for macro [22].
Duration Often long-term (years) [23]. Single procedure. Note: tumors can sometimes recur years after a ‘cured’ surgery, meaning long-term periodic blood tests are still required [24].
Key Risks Nausea, ICDs, rare heart valve issues [10][25]. General surgical risks, and rare permanent hormone deficiencies. This could mean needing to take daily replacement hormones for your thyroid or adrenal glands for the rest of your life [26].
Best For Most patients as a first-line therapy [1]. Resistant tumors, cystic tumors, or those seeking a cure [20][27].

Return to Home

Frequently Asked Questions

What is the best first-line treatment for a prolactinoma?
The standard of care is a class of medications called dopamine agonists, such as cabergoline. These drugs mimic the brain's natural signals to lower prolactin levels and successfully shrink the tumor in about 90% of patients.
When is surgery recommended instead of medication for a prolactinoma?
Transsphenoidal surgery may be recommended if your tumor does not shrink with medication or if the drug's side effects are intolerable. It is also preferred for fluid-filled cystic tumors, emergencies like sudden vision loss, or for women with large tumors planning a pregnancy.
Can prolactinoma medication affect my behavior or cause impulsivity?
Yes, in less common cases, dopamine agonists can cause impulse control disorders. This may lead to new, compulsive behaviors like pathological gambling, excessive shopping, or hypersexuality. It is important for you and your family to monitor for these changes.
How is a prolactinoma treated during pregnancy?
Pregnancy management depends on the size of your tumor. For smaller microadenomas, medication is usually stopped immediately upon a positive pregnancy test. Larger macroadenomas require specialized management and sometimes continued medication to prevent the tumor from growing.
What are the common side effects of prolactinoma medications?
Common side effects when starting medication include nausea, dizziness, and low blood pressure, especially when standing up. Taking your dose at bedtime or with a meal can help reduce these physical symptoms.

Questions for Your Doctor

  • • Is my tumor a good candidate for first-line medication, or does its size/consistency (like being cystic) make surgery a better initial option?
  • • What is the 'check-in' schedule for monitoring potential side effects like nausea or changes in my behavior (Impulse Control Disorders)?
  • • Since my tumor is large, should I have a CT scan to check for bone erosion at the base of my skull to assess the risk of a CSF leak if the tumor shrinks?
  • • If I am planning a pregnancy, should we consider surgery first to avoid the risk of the tumor growing while I'm off medication?
  • • If I get pregnant, what is the exact protocol for stopping or modifying my dopamine agonist?

Questions for You

  • • Are you comfortable with the idea of taking long-term medication, or do you prefer a more definitive (surgical) approach to reach remission?
  • • Have you or your family members noticed any new, impulsive behaviors lately, such as unusual spending, gambling, or binge eating?
  • • If you are a woman, are you currently planning a pregnancy or hope to become pregnant in the near future?
  • • How have you tolerated other medications in the past—do you tend to be sensitive to side effects like nausea or dizziness?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Cabergoline-induced fibrosis of prolactinomas: a neurosurgical perspective.

    Mohan N, Chia YY, Goh GH, et al.

    BMJ case reports 2017; (2017()) doi:10.1136/bcr-2017-220971.

    PMID: 29102970
  2. 2

    Medical management of functioning pituitary adenoma: an update.

    Oki Y

    Neurologia medico-chirurgica 2014; (54 Suppl 3()):958-65.

    PMID: 26236804
  3. 3

    Debate: Surgery as Initial Therapy for Microprolactinoma.

    Molitch ME, Mamelak AN

    The Journal of clinical endocrinology and metabolism 2025; (110(12)):e4242-e4247 doi:10.1210/clinem/dgaf434.

    PMID: 41032258
  4. 4

    Successful diagnosis and monitoring of giant prolactinomas: the role of sample dilutions.

    Schlegel A, Straseski JA

    Laboratory medicine 2025; (56(6)):786-789 doi:10.1093/labmed/lmaf021.

    PMID: 40493766
  5. 5

    The Role of Dopamine Agonists in Pituitary Adenomas.

    Giraldi EA, Ioachimescu AG

    Endocrinology and metabolism clinics of North America 2020; (49(3)):453-474 doi:10.1016/j.ecl.2020.05.006.

    PMID: 32741482
  6. 6

    How does pregnancy affect the patients with pituitary adenomas: a study on 113 pregnancies from Turkey.

    Karaca Z, Yarman S, Ozbas I, et al.

    Journal of endocrinological investigation 2018; (41(1)):129-141 doi:10.1007/s40618-017-0709-8.

    PMID: 28634705
  7. 7

    Update on prolactinomas. Part 1: Clinical manifestations and diagnostic challenges.

    Wong A, Eloy JA, Couldwell WT, Liu JK

    Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 2015; (22(10)):1562-7.

    PMID: 26256063
  8. 8

    Surgery for prolactinomas: a better choice?

    Honegger J, Nasi-Kordhishti I, Aboutaha N, Giese S

    Pituitary 2020; (23(1)):45-51 doi:10.1007/s11102-019-01016-z.

    PMID: 31853793
  9. 9

    Analysis of bromocriptine treatment in pregnant pituitary prolactinoma patients.

    Lian W, Liu N, Wang RZ, et al.

    Clinical and experimental obstetrics & gynecology 2017; (44(2)):203-207.

    PMID: 29746023
  10. 10

    Neuropsychiatric and metabolic aspects of dopaminergic therapy: perspectives from an endocrinologist and a psychiatrist.

    Athanasoulia-Kaspar AP, Popp KH, Stalla GK

    Endocrine connections 2018; (7(2)):R88-R94 doi:10.1530/EC-18-0030.

    PMID: 29378769
  11. 11

    Adverse effects produced by different drugs used in the treatment of Parkinson's disease: A mixed treatment comparison.

    Li BD, Bi ZY, Liu JF, et al.

    CNS neuroscience & therapeutics 2017; (23(10)):827-842 doi:10.1111/cns.12727.

    PMID: 28872217
  12. 12

    Impulse Control Disorders in Patients With Hyperprolactinemia on Dopamine Agonist Therapy-How Concerned Should We Be?

    Daftari G, Tritos NA

    Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2025; (31(7)):938-945 doi:10.1016/j.eprac.2025.04.018.

    PMID: 40316139
  13. 13

    Impulse control disorders in hyperprolactinemic patients on dopamine agonist therapy.

    Hamidianjahromi A, Tritos NA

    Reviews in endocrine & metabolic disorders 2022; (23(5)):1089-1099 doi:10.1007/s11154-022-09753-6.

    PMID: 36125673
  14. 14

    Untreated Giant Macroprolactinoma with Chronic Cerebrospinal Fluid Leakage: An Unusual Complication.

    Mad Naser MN, Aziz NA, Karim NKA

    Case reports in endocrinology 2019; (2019()):4825357 doi:10.1155/2019/4825357.

    PMID: 30766735
  15. 15

    Prolactinoma extension as a contributing factor in dopamine agonist-induced CSF rhinorrhea: a systematic review of the literature.

    Milton CK, Lee BJ, Voronovich ZA, et al.

    British journal of neurosurgery 2023; (37(5)):976-981 doi:10.1080/02688697.2021.1903389.

    PMID: 33783287
  16. 16

    [Overcoming therapy resistance in prolactinomas: from perspectives to real clinical practice].

    Shutova AS, Pigarova EA, Lepeshkina LI, et al.

    Problemy endokrinologii 2024; (69(6)):63-69 doi:10.14341/probl13351.

    PMID: 38311996
  17. 17

    Management of Dopamine Agonist-Resistant Prolactinoma.

    Maiter D

    Neuroendocrinology 2019; (109(1)):42-50 doi:10.1159/000495775.

    PMID: 30481756
  18. 18

    The Role of Surgery in the Management of Prolactinomas.

    Donoho DA, Laws ER

    Neurosurgery clinics of North America 2019; (30(4)):509-514 doi:10.1016/j.nec.2019.05.010.

    PMID: 31471058
  19. 19

    Management of cystic prolactinomas: a review.

    Nakhleh A, Shehadeh N, Hochberg I, et al.

    Pituitary 2018; (21(4)):425-430 doi:10.1007/s11102-018-0888-0.

    PMID: 29654440
  20. 20

    THE PLACE OF SURGERY IN THE MANAGEMENT OF PROLACTIN SECRETING ADENOMAS.

    Rotariu DI, Costachescu B, Ungureanu MC, et al.

    Acta endocrinologica (Bucharest, Romania : 2005) 2024; (20(1)):65-73 doi:10.4183/aeb.2024.65.

    PMID: 39372303
  21. 21

    'Ectopic' suprasellar type IIa PRL-secreting pituitary adenoma.

    Zhou HJ, Pan DS, Ba XQ, et al.

    Pituitary 2017; (20(4)):477-484 doi:10.1007/s11102-017-0807-9.

    PMID: 28526958
  22. 22

    Long-term follow-up of female prolactinoma patients at child-bearing age after transsphenoidal surgery.

    Yi N, Ji L, Zhang Q, et al.

    Endocrine 2018; (62(1)):76-82 doi:10.1007/s12020-018-1652-y.

    PMID: 29934876
  23. 23

    Clinical, hormonal and radiological features, and treatment outcomes of prolactinomas in a pediatric population.

    Emeksiz HC

    Northern clinics of Istanbul 2025; (12(3)):269-276 doi:10.14744/nci.2024.65049.

    PMID: 40843322
  24. 24

    A pharmacoeconomic analysis from Italian guidelines for the management of prolactinomas.

    Basile M, Valentini I, Attanasio R, et al.

    Global & regional health technology assessment 2024; (11()):1-16 doi:10.33393/grhta.2024.2601.

    PMID: 38230389
  25. 25

    [Clinical practice considerations on cabergoline in the treatment of pituitary prolactinoma].

    Ye HY, Ji LJ

    Zhonghua yi xue za zhi 2025; (105(41)):3743-3746 doi:10.3760/cma.j.cn112137-20250810-02028.

    PMID: 41218890
  26. 26

    Early outcomes of endoscopic endonasal approach pituitary adenomas resection with minimal nasal injury.

    Tao C, Cheng G, Chen Y, et al.

    Medicine 2021; (100(46)):e27843 doi:10.1097/MD.0000000000027843.

    PMID: 34797319
  27. 27

    Outcomes of Transsphenoidal Microsurgery for Prolactinomas - A Contemporary Series of 162 Cases.

    Giese S, Nasi-Kordhishti I, Honegger J

    Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 2021; (129(3)):163-171 doi:10.1055/a-1247-4908.

    PMID: 33461233

This page compares prolactinoma treatment options for educational purposes only. Always consult your endocrinologist or neurosurgeon to determine the safest and most effective treatment plan for your specific tumor.

Stay up to date

Get notified when new research about Prolactinoma is published.

No spam. Unsubscribe anytime.